The complement 3 glomerulopathy market is poised for steady growth, driven by increasing disease awareness, advances in complement pathway research, and rising diagnostic rates. The lack of approved targeted therapies has spurred significant R&D investment in complement inhibitors and novel biologics. Pipeline therapies such as KP104 (Kira Pharmaceuticals), Zaltenibart (Omeros Corporation), Ruxoprubart (NovelMed Therapeutics), ARO-C3 (Arrowhead Pharmaceuticals), and others are expected to reshape the treatment landscape over the next decade.
New York, USA, Oct. 22, 2025 (GLOBE NEWSWIRE) — Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025-2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
The complement 3 glomerulopathy market is poised for steady growth, driven by increasing disease awareness, advances in complement pathway research, and rising diagnostic rates. The lack of approved targeted therapies has spurred significant R&D investment in complement inhibitors and novel biologics. Pipeline therapies such as KP104 (Kira Pharmaceuticals), Zaltenibart (Omeros Corporation), Ruxoprubart (NovelMed Therapeutics), ARO-C3 (Arrowhead Pharmaceuticals), and others are expected to reshape the treatment landscape over the next decade.
DelveInsight’s Complement 3 Glomerulopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of individual therapies, and current and forecasted complement 3 glomerulopathy market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
Complement 3 Glomerulopathy Market Summary
Discover which complement 3 glomerulopathy medications are expected to grab the market share @ Complement 3 Glomerulopathy Market Report
Key Factors Driving the Growth of the Complement 3 Glomerulopathy Market
Growing C3G Patient Population
In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved diagnostics, and wider use of genetic testing, complement assays, and multidisciplinary biopsy evaluation.
Advancements in Targeted Therapies
The development of targeted therapies, such as complement inhibitors, has improved treatment options for C3G. These therapies aim to regulate the complement system, addressing the underlying cause of the disease. Notable drugs in this category include Pegcetacoplan (EMPAVELI/ ASPAVELI) and Iptacopan (FABHALTA/ FABIHARTA), which have shown promise in clinical trials.
Expected Launch of C3G Drugs
Key players such as Kira Pharmaceuticals (KP104), Omeros Corporation (Zaltenibart [OMS906]), NovelMed Therapeutics (Ruxoprubart [NM8074]), Arrowhead Pharmaceuticals (ARO-C3), and others are currently developing drugs for C3G. These therapies are expected to create an upward shift in the C3G treatment market after their launch in the coming years, in the 7MM.
Emergence of Novel Mechanisms in C3G
Emerging therapies targeting novel mechanisms such as dual complement inhibitors (C5 and Factor H (KP104), MASP-3 inhibitors (Zaltenibart), RNA interference (RNAi) therapeutics targeting complement C3 (ARO-C3), and others are showing promise as potential treatment options.
Complement 3 Glomerulopathy Market Analysis
The management of C3G largely depends on the off-label use of multiple prescription medications, underscoring the significant unmet need for approved and targeted treatments. Current therapeutic strategies primarily involve immunosuppressants, corticosteroids, Renin-Angiotensin-Aldosterone System (RAAS) inhibitors, and supportive agents like calcineurin inhibitors and monoclonal antibodies.
Additional off-label approaches include the use of monoclonal antibodies such as eculizumab and rituximab, which act on the terminal complement pathway by inhibiting C5, leading to improved kidney function and reduced proteinuria.
FABHALTA was the first drug to receive approval for C3G treatment, followed by EMPAVELI/ASPAVELI, developed by Apellis Pharmaceuticals and Sobi. Nonetheless, both therapies face a key limitation, black box warnings for potentially fatal infections caused by encapsulated bacteria (e.g., Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type b), requiring patients to be vaccinated at least two weeks prior to therapy initiation.
EMPAVELI/ASPAVELI represents a promising treatment option by targeting C3 directly and upstream in the complement cascade. It has demonstrated superior clinical efficacy, nearly doubling the therapeutic benefits achieved with FABHALTA, setting a new benchmark for treatment effectiveness.
Meanwhile, emerging investigational therapies focusing on novel mechanisms, such as dual complement inhibition (C5 and Factor H; KP104), MASP-3 inhibition (Zaltenibart), and RNA interference (RNAi) therapeutics targeting complement C3 (ARO-C3), are showing encouraging potential as future treatment options.
Learn more about the complement 3 glomerulopathy treatment options @ Complement 3 Glomerulopathy Treatment Market
Complement 3 Glomerulopathy Competitive Landscape
The emerging pipeline of C3G holds a few significant products in development by prominent key players such as Kira Pharmaceuticals (KP104), Omeros Corporation (Zaltenibart [OMS906]), NovelMed Therapeutics (Ruxoprubart [NM8074]), Arrowhead Pharmaceuticals (ARO-C3), and others.
Kira Pharmaceuticals’ KP104 is a potent, first-in-class bifunctional biologic engineered to concurrently and selectively inhibit both the alternative and terminal complement pathways. This dual mechanism offers a robust and synergistic approach to addressing key drivers of complement-mediated diseases. The therapy is advancing into Phase II proof-of-concept studies across multiple high-need indications, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), systemic lupus erythematosus-associated thrombotic microangiopathy (SLE-TMA), and paroxysmal nocturnal hemoglobinuria (PNH). These global Phase II trials will take place in the United States, China, Australia, and South Korea.
Omeros Corporation’s Zaltenibart is an investigational human monoclonal antibody that targets mannan-binding lectin-associated serine protease-3 (MASP-3), a critical upstream activator of the complement system’s alternative pathway. Upon successful completion of the Phase II trial and demonstration of strong efficacy, Omeros Corporation intends to initiate a Phase III study in C3G.
The anticipated launch of these emerging complement 3 glomerulopathy therapies are poised to transform the complement 3 glomerulopathy market landscape in the coming years. As these cutting-edge complement 3 glomerulopathy therapies continue to mature and gain regulatory approval, they are expected to reshape the complement 3 glomerulopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about new treatment for complement 3 glomerulopathy, visit @ Complement 3 Glomerulopathy Medication
Recent Developments in the Complement 3 Glomerulopathy Market
What is Complement 3 Glomerulopathy?
Complement 3 glomerulopathy (C3G) is a glomerular disorder marked by dominant deposition of the C3 complement component within the glomeruli, with minimal or no presence of immunoglobulins and no deposition of C1q or C4. The accumulation of C3, in the absence of classical or lectin pathway components, indicates that the disease arises from dysregulation of the alternative complement pathway. The presence of C3 deposits without significant immunoglobulin, in a patient showing typical signs of glomerulonephritis, serves as the defining diagnostic feature. Due to its rarity, accurate estimates of the incidence and prevalence of C3G are difficult to obtain, and current figures are based on small cohort studies with limited reliability.
Complement 3 Glomerulopathy Epidemiology Segmentation
The complement 3 glomerulopathy epidemiology section provides insights into the historical and current complement 3 glomerulopathy patient pool and forecasted trends for the leading markets. The diagnosed prevalent population of C3G, in the United States, was found to be 3,400 in 2024.
The complement 3 glomerulopathy market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets segmented into:
Download the report to understand complement 3 glomerulopathy management @ Complement 3 Glomerulopathy Treatment Options
Scope of the Complement 3 Glomerulopathy Market Report
Discover more about complement 3 glomerulopathy drugs in development @ Complement 3 Glomerulopathy Clinical Trials
Complement 3 Glomerulopathy Clinical Trial Analysis
Complement 3 Glomerulopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Complement 3 Glomerulopathy companies, including ChemoCentryx, Novartis Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals, among others.
Immune Complex Membranoproliferative Glomerulonephritis Market
Immune Complex Membranoproliferative Glomerulonephritis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IC-MPGN companies, including Novartis Pharmaceuticals, Apellis Pharmaceuticals, among others.
IgA Nephropathy Market
IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key IgAN companies, including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, among others.
Glomerulonephritis Market
Glomerulonephritis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key glomerulonephritis companies, including Alentis Therapeutics, Takeda Pharmaceutical, Biogen, Novartis, Nkarta, Vertex Pharmaceuticals, Vera Therapeutics, Sobi, Travere Therapeutics, among others.
Glomerulonephritis Clinical Trial Analysis
Glomerulonephritis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glomerulonephritis companies, including Alentis Therapeutics, Takeda Pharmaceutical, Biogen, Novartis, Nkarta, Vertex Pharmaceuticals, Vera Therapeutics, Sobi, Travere Therapeutics, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
